Saturday, October 3, 2026

AUD/USD Went Down By Over 3% In The Last 21 Sessions

AUD/USD Went Down By Over 3% In The Last 21 Sessions

(VIANEWS) - AUD/USD (AUDUSD) has been up by 3.09% for the last 21 sessions. At 08:09 EST on Wednesday, 7 August, AUD/USD (AUDUSD) is $0.66.

Aud/usd attracts some buyers near 0.6550 amid rba’s hawkish stance, bigger fed rate cut bets

The AUD/USD pair extends the recovery near 0.6545 on Wednesday during the early European trading hours.

AUD/USD's yearly highs and lows, it's 4.64% up from its 52-week low and 7.459% down from its 52-week high.

Previous days news about AUD/USD (AUDUSD)

  • Aud/usd recovers from intraday lows near 0.6350 as US dollar plummets. According to FXStreet on Monday, 5 August, "The AUD/USD pair bounces back strongly after posting a fresh eight-month low near 0.6350 in Monday's European session. "
  • Aud/usd surrenders major part of hawkish rba-inspired gains, back around 0.6500 mark. According to FXStreet on Tuesday, 6 August, "The AUD/USD pair attracts fresh sellers following an intraday uptick to the 0.6540 region and drops to the lower end of its daily range during the first half of the European session on Tuesday. ", "This, along with a positive turnaround across the global equity markets, offered some support to the AUD/USD pair."
  • Aud/usd edges higher to near 0.6500 in the aftermath of RBA policy meeting. According to FXStreet on Tuesday, 6 August, "The AUD/USD pair gains slightly to near the psychological figure of 0.6500 in Tuesday's New York session. "

More news about AUD/USD (AUDUSD).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com